Kinase and Signaling Pathway Dependencies Driving Cancer Therapeutic Response

• 316 · PDF Subcellular localization of PARP1 by protein kinase D1 modulated cellular response to olaparib Sanjeev Shukla, Joseph McGrath, Robert Willis, Arjun Venkatesh, Jean-Pierre Kanumuambidi, Reynier Rodriguez-Rosales, Mario Mietzsch, Robert McKenna, K.C. Balaji
• 317 Glucose conditions influence CAMKK2-targeted therapy sensitivity in triple-negative breast cancer of different ancestry Elham Amini, Sree latha Aramgam, Kenisha Webb, Sean Kimbro
• 318 · PDF The combination of STX-478 and lorlatinib for the treatment of PIK3CA mutant colorectal cancer Addison T. Zick, Alexa E. Schmitz, Cheri A. Pasch, Dustin A. Deming
• 319 An analysis of orthosteric missense kinase mutations among a clinical sequencing cohort of over 90,000 cancer patients Jessica B. White, John D. Chodera, Wesley Tansey
• 320 Targeting overexpressed TTK and NEK2 decreases early metastatic potential of triple-negative breast cancer cell lines Alexandra N. Aquino-Acevedo, Ángel D. Colón-Burgos, Esther M. Irizarry-Quintana, Elliott Rodriguez-Lopez, Joel A. Orengo-Orengo, Marileana Rodriguez-Ruiz, Gretchen M. Albarrán-Acosta, Melanie E. Cruz-Robles, Harold I. Saavedra
• 321 · PDF PTPN1 activates neuroendocrine of treatment emergent prostate cancer by targeting the AR and REST complex Yu-An Chen, Mickey Glover, Rey-Chen Pong, Payal Kapur, Jer-Tsong Hsieh
• 322 Differential effects of SRPK1 inhibition on HPV⁺ and HPV⁻ in cervical cancer: Transcriptome and splicing rewiring Afra Tsitsi Basera, Mohammed Alaouna, Janie Duvanhage, David Bates, Zodwa Dlamini, Rahaba Marima
• 323 Dual inhibition of SIK2/3 induces ER Stress and ER-phagy, enhancing the cytotoxicity of autophagy blockade in ovarian cancer Rumeysa Ozyurt, Gamze Bildik Elcik, Weiqun Mao, Robert C. Bast, Zhen Lu
• 324 · PDF ASCL1-mediated transcriptional regulation of RET in neuroendocrine prostate cancer Sachi B. Tengse, Song Yi Bae, Hannah E. Bergom, Ella Boytim, Halena R. VanDeusen, Quynh Chau Dinh, Abderrahman Day, Rayhan Biswas, Farzana Kabir, Laura E. Hirsch, Yingtian Xie, Daniel A. Harki, Sylvan C. Baca, Henry Long, John K. Lee, Leigh Ellis, Justin Hwang, Justin M. Drake
• 325 Development of the pyridopyrimidine derivative KC12 as a selective dual Pim/Mnk inhibitor to inhibit leukemia cell growth Linxiang Zhao, Kun Xing, Jingyi Zhang, Shuwei Zuo, Fuyao Zhang, Samuel Waxman, Yongkui Jing
• 326 Association of off targets of ALK inhibitors with their adverse reactions revealed by a novel comprehensive phosphorylation profiling platform Katsuhisa Horimoto, Satoshi Mikami, Lili Feng, Yu Zhang, Dongyin Chen, Feng Han, Satoshi Yamasaki, Shota Takei, Hiroshi Kagamu
• 327 MARK2/MARK3/MARK4 kinases are therapeutic targets for human head and neck squamous cell carcinoma with co-dependencies of YAP-TEAD pathway Se Eung Oh, Hwan Jung Lim, Seong Jun Park, Sang Uk Han, Jee Hung Kim, Seo Young Lee, Hei-Cheul Jeung
• 328 · PDF Establishment of assay systems for drug development against the oncogenic phosphatase WIP1 Daniel Feger, Daniel Müller, Lena Pilgermayer, Carolin Heidemann-Dinger, Sarah Ulrich, Michael Kubbutat, Holger Weber, Joe Lewis, Birgit Zech, Jan E. Ehlert
• 329 PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models Sreeja Sreekumar, Elodie Montaudon, Zeena Eblimit, Migdalia Gonzalez, Davis Klein, Heloise Derrien, Ahmed Dahmani, Tod Smeal, Elisabetta Marangoni, Maya Ridinger
• 330 · PDF EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions Carol Gao, David Gonzalez Martinez, Sofia Wissert, Hana Bader, Nidhi Sahni, Anh T. Le, Robert C. Doebele, Lukasz Bugaj
• 332 AKT1 mediated post translational modification of the glucocorticoid receptor drives resistance to prostate cancer therapy Surendra Gulla, Tej Sharma, Ephraim Gardner, Abbas Jawadala, Sasikumar Ponnusamy, Tobi Ogunbowale, Maddie Aust, Jonathan E. Bard, Remi Adelaiye-Ogala
• 333 Downregulation of AURKA and AURKB promotes a decrease in cell invasion in TNBC by modulating the expression of SNAIL1 Joel Alexis Orengo Orengo, Elliott Rodriguez-Lopez, Selimar Álvarez Velázquez, William Frank Rodríguez, Alexandra N. Aquino-Acevedo, Melanie E. Cruz Robles, Harold Ivan Saavedra
• 334 A novel inhibitor of the atypical protein kinase C-ι decreases the proliferation of malignant gastric cancer cells and disrupts the Skp-2 pathway Abiral Hasib Shourav, Nuzhat Nowshin Oishee, Abigail Oluwafisayo Olatunji, Mahfuza Marzan, Khandker M. Khalid, Radwan Ebna Noor, Shreejana Rimal, Mildred Acevedo-Duncan
• 335 Inhibition study of protein kinase C-iota mediated signaling pathways in diffuse midline glioma by ICA-1S inhibitor and temozolomide Radwan Ebna Noor, Nuzhat Nowshin Oishee, Abir Hasib Shourav, Mahfuza Marzan, Javad Nazarian, Michelle Monje, Mildred Acevedo-Duncan
• 336 Modular control of Pancreatic ductal adenocarcinoma (PDAC) progression by the substrate interaction domains of ERK2 Monika Verma, Billy Truong, Sven Miller, Rachael Price, Dietmar Kappes, Paul Shapiro, Igor Astsaturov, David L. Wiest
• 337 Off-target activation of GCN2 by BRAF V600 inhibitors attenuates melanoma outgrowth C. Ryland Ill, Nasreen C. Marikar, Vu T. Nguyen, Brianna Fernandez, Varuna Nangia, Alicia M. Darnell, Matthew G. Vander Heiden, Philip Reigan, Sabrina L. Spencer
• 338 · PDF Discovery of novel pan-PI3K and mTOR dual inhibitors as first-in-class antibody-drug conjugate payloads Qi Liu, Lan Pham, Chin Pan, Jin Wang, Kamaldeep S. Dhami, Yingchun Li, Jeffrey Serrill, Ravi Kasiappan, Felix DeAnda, Screenivas Punna, Karl Haelsig, Apeksha Villath, Ketaki Gadkari, Geunbae Rha, Deanna Haasch, Albert Lai, James W. Purcell, Xueqing Wang

在完整检索应用中浏览本分会场 →